Antiviral Drugs Market Outlook

The antiviral drugs market is anticipated to flourish at an average CAGR of 3.9% between 2023 and 2033. The market is expected to hold a market share of US$ 89.68 billion by 2033, while the market is likely to reach a value of US$ 61.42 billion in 2023.

Attributes Details
Antiviral Drugs Market CAGR (2023 to 2033) 3.9%
Antiviral Drugs Market Size (2023) US$ 61.42 billion
Antiviral Drugs Market Size (2033) US$ 89.68 billion

Antiviral drugs are medicines that are used especially for treating viral infections. Most antiviral drugs are used for particular viral infections, similar to antibiotics, while a broad-spectrum antiviral drug is effective against a varied range of viruses. Antiviral drugs do not kill their target pathogen. Instead, they inhibit the development of those viruses.

The global antiviral drugs market is projected to register a moderate growth rate in the pharmaceutical market and is anticipated to increase due to a rise in awareness level, an increase in the diseased population, and the introduction of new drugs with improved efficacy.

Some key patents are reaching their expiry during the forecast periods, such as Combivir, Sustiva, Tenofovir, Tamiflu, Relenza, and Telbivudine. The patent expiries of these blockbuster drugs are expected to trigger generic competition in the antiviral therapeutics market, making the market more competitive.

The late-stage pipeline drugs are expected to enter the market, positively impacting the market. Most antivirals are considered comparatively harmless to the host and therefore are used to treat infections. They are different from viricides, which are not used for medication but can destroy or deactivate virus particles outside or inside the body. Antiviral drugs are used in the treatment of patients suffering from herpes viruses, HIV, influenza A and B viruses, and hepatitis B and C viruses.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Antiviral Drugs Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)

The global demand for antiviral drugs is projected to increase at a CAGR of 3.9% during the forecast period between 2023 and 2033, reaching a total of US$ 89.68 billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3.8%.

During the historical outlook, the biggest driver of the overall antiviral drugs market was Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales, which accounted for more than half the share of the market in 2021. According to WHO, in 2021, several patients living with HIV are 38.4 million, and 650k people acquired the disease in the same year.

Nearly four out of five people were freshly put on treatment in sub-Saharan Africa. In 21 African countries with a high burden of HIV, two out of three people in need are receiving treatment, and two out of three positive pregnant women are receiving antiretroviral drugs to prevent HIV transmission to their infants. The introduction of solid R&D activities, newer and advanced treatments, and formulations, such as vaccines and combination therapy, are projected to fuel the market growth of antiviral drugs over the forecast period.

Which Drivers underpin Antiviral Drugs Industry Expansion?

The increasing commonness of viral infections such as HIV, Herpes, Influenza, and others is expected to upsurge the demand for antiviral medicines throughout the forecast period. For instance, according to UNAIDS, in 2020, more than 37 billion individuals were living with HIV across the globe. Out of these, around 1.5 billion new people acquired HIV infection in 2020. Overall, the COVID-19 pandemic has pointedly accelerated the market growth in 2021, whereas a negative impact of the pandemic has been detected for other applications of antiviral drugs.

Owing to solid R&D activities, newer and advanced treatments, and formulations, such as vaccines, combination therapy, and others, are being introduced in the market, and the demand is anticipated to upsurge. Hence, strong R&D is one of the crucial factors in the antiviral drugs market growth.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Which Factors are limiting the Growth of the Antiviral Drugs Market?

Several factors hampering the market expansion of Antiviral Drugs include the high risk of failure, the high cost of R&D and therapy, and government austerity. However, the swelling usage of natural products and the high cost of developing drugs are the market's key challenges.

Country-wise Insights

Countries Revenue Share % (2022)
United States 7.1%
Germany 5.8%
Japan 6.4%
North America 38.7%
Europe 24.9%
Countries CAGR % (2023 to 2033)
China 4.7%
India 3.8%
United Kingdom 2.7%
Australia 3.4%

North America Holds a Significant Position in the Global Antiviral Drugs Market

In terms of market contribution, North America acquired the leading share in revenue collection across the globe, accounting for a 38.7% share in 2022. As per the recent analysis by Future Market Insights, the region is anticipated to maintain its dominance during the assessment period 2022-2032. The United States and Canada are estimated to be the leading shareholders in regional revenue generation.

The market decline can be attributed to the loss of market exclusivity of patented drugs, mounting vaccination rates against viral infections, and government initiatives to minimize the prevalence of viral infections.

For instance, the United States government is responsible for several measures, including funding and grants in infectious diseases programs and encouraging the R&D activities of innovative therapies to manage viral infections.

How Growth of the European Antiviral Drugs Market May Unfold?

Based on the geographies, European is the second-leading region, acquiring a 24.9% share in the antiviral drugs market. During the forecast period, the region is estimated to witness moderate growth, backed by soaring investments in the development of new drugs and therapies. This market growth is also attributed to the easy approval and promising healthcare policies by several governments.

In April 2022, European Medicines Agency, the European Union's drug regulator, signed off on emergency usage of Merck's Covid antiviral pill for adults who get tested positive as it prepares to decide on full approval by the year's end.

In July 2021, GSK and Vir announced a Joint Procurement Agreement (JPA) with the European Commission to supply up to 220,000 doses of sotrovimab. Following the grant of the marketing authorization in the EU, Member States participating in the JPA can now order sotrovimab to support their pandemic responses. These initiatives are likely to fuel the market growth of Antiviral Drugs in the coming years.

How is the APAC Region Bolstering the Demand for Antiviral Drugs?

In the Asia Pacific, the market for antiviral drugs is anticipated to witness the fastest growth rate throughout the forecast period. The market's exponential growth can be attributed to the rising prevalence and treatment rate of viral infections, emerging healthcare infrastructure in the region, and growing awareness among people regarding infectious diseases.

Besides, the strong presence of generic pharmaceutical manufacturing companies in India, China, and other South Asian countries and the rising geriatric population in the region are some principal driving factors of the segment.

The introduction of new and innovative strategies in emerging economies is also likely to boost the demand for Antiviral Drugs over the coming decade.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category Analysis

Category By Application Type
Leading Segment HIV
Market Share (2022) 44.0%
Category By End Use
Leading Segment Hospitals
Market Share (2022) 47.80%

By Application, Which Antiviral Drugs Category May Remain Prominent?

The global antiviral drugs market is segmented based on product type and end user. The HIV segment captured the majority share in terms of market revenue generation and held the leading revenue share of 44.0% in 2022.

The segment is projected to observe the fastest growth rate over the forecast period. The rising prevalence of HIV infection associated with a high treatment rate, availability of branded drugs, and government initiatives to upsurge the treatment rate is projected to stimulate the market at a higher growth rate.

For instance, in 2019, the United States government introduced the Ending the HIV Epidemic (EHE) plan to end the HIV epidemic in the country by 2032. The initiative seeks to decrease HIV infections and enhance the diagnosis and treatment rate in the United States. Furthermore, the existence of strong pipeline drugs for HIV infection may also fuel market growth throughout the conjecture period.

The hepatitis segment held the second-leading revenue share in 2021. Escalating vaccination against hepatitis A and B is affecting the growth adversely. Besides, the COVID-19 pandemic has significantly augmented the growth of the other segment in 2020.

The Start-up Ecosystem: How Key Players Are Opening Frontiers for Future Growth?

  • Founded in 2010, New American Therapeutics is a United States-based specialty pharmaceutical company. The company acquires, markets, and develops therapeutic products for infectious diseases. It develops Denavir, a topical antiviral drug for the treatment of recurrent herpes labialis in adults and children 12 years of age and older. Denavir was acquired from Novartis in 2010
  • Founded in 2009, Adaptive Biotechnologies is a United States-based provider of clinical diagnostics and drug discovery for immune diseases. The company's immune profiling sequencing technology, immunoSEQ, enables the characterization of the immune system, helping scientists & clinicians in research and drug development. The company also offers clonoSEQ for monitoring Minimal Residual Disease (MRD) in blood-based cancers. Also, develops cell therapies, vaccines, and antibody molecules for infectious diseases.

Competitive Landscape

Recent Developments:

  • In May 2022, Cipla Limited, in partnership with Genes2Me Pvt. Ltd., announced the commercialization of the 'RT-Direct' multiplex COVID-19 RT PCR Test kit in India. Cipla is increasing its diagnostics portfolio in an attempt to take more innovative and innovative solutions to the market.
  • In May 2022, Abbott reached an agreement with the Food and Drug Administration on Monday to reopen the company's manufacturing plant in Michigan to help ease a nationwide shortage of baby formula after the facility was closed due to bacterial contamination.
  • In March 2022, Scripps Research, non-profit research and technology drug discovery organization, and AbbVie Inc. established a strategic collaboration to investigate novel, immediate antiviral treatments for COVID-19.
  • The European Commission has approved Roche's Xofluza for the advanced treatment of influenza. The commission has approved the single dose for patients.
  • Gilead has introduced Veklury for pediatric patients that are hospitalized and not hospitalized.

Key Players

  • Roche
  • Gilead
  • GlaxoSmithKline
  • Bristol-Myers-Squibb
  • Abbott
  • AstraZeneca
  • Cipla
  • Bayer AG
  • Johnson & Johnson
  • Merck & Co
  • AbbVie
  • Aurobindo Pharma
  • Dr. Reddy’s Laboratories Ltd.

Key Segments Covered

By Product type:

  • Hepatitis-C antivirals
  • HIV antivirals
  • Herpes antivirals
  • Hepatitis-B antivirals
  • Influenza antivirals
  • Others (Pneumonia, Flu, etc.)

By End User:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers

Key Regions Covered:

  • North America
    • United States
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • United Kingdom
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Japan
  • Asia Pacific Excluding Japan
    • China
    • India
    • Malaysia
    • Singapore
    • Australia
    • Rest of Asia Pacific Excluding Japan (APEJ)
  • The Middle East and Africa
    • GCC Countries
    • Israel
    • South Africa
    • Middle East and Africa (MEA)

Frequently Asked Questions

How Big is the Antiviral Drugs market?

The market is valued at US$ 61.42 billion in 2023.

Who are the key Antiviral Drugs Market Players?

AstraZeneca, Cipla, Bayer AG are the key market players.

What is the Growth Potential of the Antiviral Drugs Market?

The growth potential of the market is 3.9% through 2033.

What is the Projected Market Value 2033?

The market is estimated to reach US$ 89.68 billion by 2033.

How is the Historical Performance of the Market?

The market registered a CAGR of 3.8% from 2018 to 2022.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Product type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product type, 2023 to 2033

        5.3.1. Hepatitis-C antivirals

        5.3.2. HIV antivirals

        5.3.3. Herpes antivirals

        5.3.4. Hepatitis-B antivirals

        5.3.5. Influenza antivirals

        5.3.6. Others

    5.4. Y-o-Y Growth Trend Analysis By Product type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Product type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-user

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By End-user, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-user, 2023 to 2033

        6.3.1. Hospitals

        6.3.2. Clinics

        6.3.3. Ambulatory Surgical Centers

    6.4. Y-o-Y Growth Trend Analysis By End-user, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By End-user, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Western Europe

        7.3.4. Eastern Europe

        7.3.5. South Asia and Pacific

        7.3.6. East Asia

        7.3.7. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. U.S.

            8.2.1.2. Canada

        8.2.2. By Product type

        8.2.3. By End-user

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Product type

        8.3.3. By End-user

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Product type

        9.2.3. By End-user

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Product type

        9.3.3. By End-user

    9.4. Key Takeaways

10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. U.K.

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Western Europe

        10.2.2. By Product type

        10.2.3. By End-user

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Product type

        10.3.3. By End-user

    10.4. Key Takeaways

11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Poland

            11.2.1.2. Russia

            11.2.1.3. Czech Republic

            11.2.1.4. Romania

            11.2.1.5. Rest of Eastern Europe

        11.2.2. By Product type

        11.2.3. By End-user

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Product type

        11.3.3. By End-user

    11.4. Key Takeaways

12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Bangladesh

            12.2.1.3. Australia

            12.2.1.4. New Zealand

            12.2.1.5. Rest of South Asia and Pacific

        12.2.2. By Product type

        12.2.3. By End-user

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Product type

        12.3.3. By End-user

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Product type

        13.2.3. By End-user

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Product type

        13.3.3. By End-user

    13.4. Key Takeaways

14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Product type

        14.2.3. By End-user

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Product type

        14.3.3. By End-user

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. U.S.

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Product type

            15.1.2.2. By End-user

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Product type

            15.2.2.2. By End-user

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Product type

            15.3.2.2. By End-user

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Product type

            15.4.2.2. By End-user

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Product type

            15.5.2.2. By End-user

    15.6. U.K.

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Product type

            15.6.2.2. By End-user

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Product type

            15.7.2.2. By End-user

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Product type

            15.8.2.2. By End-user

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Product type

            15.9.2.2. By End-user

    15.10. Poland

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Product type

            15.10.2.2. By End-user

    15.11. Russia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Product type

            15.11.2.2. By End-user

    15.12. Czech Republic

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Product type

            15.12.2.2. By End-user

    15.13. Romania

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Product type

            15.13.2.2. By End-user

    15.14. India

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Product type

            15.14.2.2. By End-user

    15.15. Bangladesh

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Product type

            15.15.2.2. By End-user

    15.16. Australia

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Product type

            15.16.2.2. By End-user

    15.17. New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Product type

            15.17.2.2. By End-user

    15.18. China

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Product type

            15.18.2.2. By End-user

    15.19. Japan

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Product type

            15.19.2.2. By End-user

    15.20. South Korea

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Product type

            15.20.2.2. By End-user

    15.21. GCC Countries

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Product type

            15.21.2.2. By End-user

    15.22. South Africa

        15.22.1. Pricing Analysis

        15.22.2. Market Share Analysis, 2022

            15.22.2.1. By Product type

            15.22.2.2. By End-user

    15.23. Israel

        15.23.1. Pricing Analysis

        15.23.2. Market Share Analysis, 2022

            15.23.2.1. By Product type

            15.23.2.2. By End-user

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Product type

        16.3.3. By End-user

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Roche

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Gilead

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. GlaxoSmithKline

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Bristol-Myers-Squibb

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Abbott

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. AstraZeneca

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Cipla

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Bayer AG

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Johnson & Johnson

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Merck & Co

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

        17.1.11. AbbVie

            17.1.11.1. Overview

            17.1.11.2. Product Portfolio

            17.1.11.3. Profitability by Market Segments

            17.1.11.4. Sales Footprint

            17.1.11.5. Strategy Overview

                17.1.11.5.1. Marketing Strategy

        17.1.12. Aurobindo Pharma

            17.1.12.1. Overview

            17.1.12.2. Product Portfolio

            17.1.12.3. Profitability by Market Segments

            17.1.12.4. Sales Footprint

            17.1.12.5. Strategy Overview

                17.1.12.5.1. Marketing Strategy

        17.1.13. Dr. Reddy’s Laboratories Ltd.

            17.1.13.1. Overview

            17.1.13.2. Product Portfolio

            17.1.13.3. Profitability by Market Segments

            17.1.13.4. Sales Footprint

            17.1.13.5. Strategy Overview

                17.1.13.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Recommendations

Healthcare

Antiviral Immunoglobulin Market

July 2017

REP-GB-4398

June 2023

240 pages

Explore Healthcare Insights

View Reports